adhesion G protein-coupled receptor F3Genealiases: GPR113 · PGR23
Q-omics provides the consensus-scored ADGRF3 profile across patient tissues and cancer cell-line models. ADGRF3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ADGRF3 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ADGRF3 RNA expression shows 19,475 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where ADGRF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRF3 survival associations across molecular data types. ADGRF3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRF3 RNA expression–survival associations across cancer types. High ADGRF3 expression shows unfavorable associations in ACC, KIRC and LIHC, but favorable associations in BLCA, HNSC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ADGRF3 RNA expression.
This table summarizes ADGRF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADGRF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRF3 shows lower tumor expression in KIRC, KICH, THCA, KIRP and BRCA and higher tumor expression in CHOL. The KIRC box plot shows higher ADGRF3 RNA expression in normal versus tumor tissue (log2 FC = −1.845, t-test p < 0.001).
This table shows molecular features associated with ADGRF3 in patient tissues and cancer cell lines. In patient samples, ADGRF3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
